Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients

British Journal of Ophthalmology

Volumn 91, Issue 12, 2007, Pages 1662-1666

  Leonardi, A ^a,b   Bremond Gignac, D ^c   Bortolotti, M ^b   Violato, D ^b   Pouliquen, P ^d   Delval, L ^d   Grouin, J M ^e   Fregona, I A ^b  

^a Ophthalmology Unit   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d Laboratoires Thea   (France)

^e UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; LEVOCABASTINE; N ACETYLASPARTYLGLUTAMIC ACID; NAAXIA SINE; UNCLASSIFIED DRUG;

ARTICLE; BURNING SENSATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; FEMALE; GASTRITIS; HUMAN; MALE; PRIORITY JOURNAL; VERNAL CONJUNCTIVITIS; VISUAL ACUITY;

ANTI-INFLAMMATORY AGENTS; CHILD; CONJUNCTIVITIS, ALLERGIC; DIPEPTIDES; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LYMPHOCYTE COUNT; MALE; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PILOT PROJECTS; PIPERIDINES; PRESERVATIVES, PHARMACEUTICAL; TEARS; TREATMENT OUTCOME;

EID: 36749102672     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.117515     Document Type: Article

References (33)

1. Leonardi A, Borghesan F, Avarello A, et al. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br J Ophthalmol 1997;81:23-6.
2. Tabbara KF, al Kharashi SA. Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br J Ophthalmol 1999;83:180- 4.
3. Bonini S, Coassin M, Aronni S, et al. Vernal keratoconjunctivitis. Eye 2004;18:345-51.
4. Lee Y, Raizman MB. Vernal conjunctivitis. Immunol Allergy Clin North Am 1997;17:33-51.
5. Leonardi A, Smith LM, Secchi AG. Vernal keratoconjunctivitis. In: Abelson MB, eds. Allergic diseases of the eye. Philadelphia: Saunders, 2000:179-96.
6. Montan PG, Hage-Hamsten M. Eosinophil cationic protein in tears in allergic conjunctivitis. Br J Ophthalmol 1996;80:556-60.
7. Leonardi A, Borghesan F, Faggian D, et al. Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. Allergy 1995;50:610-3.
8. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002;21:319-39.
9. Trocme SD, Aldave AJ. The eye and the eosinophil. Surv Ophthalmol 1994;39:241-52.
10. Trocme SD, Kephart GM, Allansmith MR, et al. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol 1989;108:57-63.
11. Trocme SD, Gleich GJ, Kephart GM, et al. Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 1994;35:3051-6.
12. Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol 2000;129:151-8.
13. Trocme SD, Kephart GM, Bourne WM, et al. Eosinophil granule major basic protein deposition in corneal ulcers associated with vernal keratoconjunctivitis. Am J Ophthalmol 1993;115:640-43.
14. Djennas M, Benia ML, Brahimi O. Le traitement de la conjonctivite printanière: étude clinique de l'acide N-acetyl-aspartyl- glutamique* en collyre. Objectif Médical 1986;2:8-9.
15. van Bijsterveld OP, Aalders-Deenstra V. Klinische Erprobung von N-acetyl-aspartyl-Glutaminsaure Augentropfen bei subakuter und chronischer atopischer Konjunktivitis. Klin Monatsbl Augenheilkd 1986;188:625-7.
16. Vingtain P. Traitement des limbo-conjonctivites endémiques des tropiques (L.C.E.T.): Etude clinique de l'acide N-acétyl- aspartyl-glutamique en collyre. Objectif Médical 1991;85:1-3.
17. Etievant M, Leluc B, David B. In vitro inhibition of the classical and alternate pathways of activation of human complement by N-acetyl aspartyl glutamic acid (NAAGA). Agents Actions 1988;24:137-44.
18. Goldschmidt P, Bazan HEP, Hurst J, et al. Effects of N-acetyl aspartyl glutamic acid (NAAGA) in rabbit cornea anterior segment inflammation. ARVO. Sarasota, USA, May 2-7, 1993. Invest Ophthalmol Vis Sci 1993;34:3475-85.
19. Goldschmidt P, Blondin C, Haeffner-Cavaillon N. Anti-inflammatory activity of the dipeptide Naaga assessed with human circulating eosinophils. ARVO. Fort Lauderdale, USA, May 11-16, 1997. Invest Ophthalmol Vis Sci 1997;38:5027-B534.
20. Goldschmidt PL, Vulliez-Le Normand B, et al. Effects of N-acetyl-aspartyl glutamic acid and sodium cromoglycate on leukotriene B4 secretion by human leukocytes. Allergy 1990;45:363-9.
21. Jambou D, Lapalus P. Effect of N-acetyl-aspartyl-glutamate (Naaga) on in-vitro leukotriene synthesis by macrophage cell line P388D1. Int J Tissue React 1990;12:273-80.
22. Goldschmidt P, Blondin C, Boulhal H, et al. Cell-adhesion molecules (CD11b) and Rantes-expression are inhibited in human eosinophils by the dipeptide NAAGA. First Combined International Symposium on Ocular Immunology and Inflammation. Amsterdam, The Netherlands, June 27-July 1, 1998. Ocul Immunol Inflamm 1998;6:S16.
23. Goldschmidt P, Boulhal H, Cavaillon N. Induction on human eosinophils (Eo) of transmembrane cell adhesion molecules (VLA-4/CD49) by histamine (H) and its inhibition by N-acetyl-aspartyl glutamate (Naaga). ARVO. Fort Lauderdale, USA, May 9-14, 1999. Invest Ophthalmol Vis Sci 1999;40:3608-B466.
24. Goldschmidt P, Luyckx J. Effects of lodoxamide (LOD), disodium cromoglycate (DSCG) and N-acetyl-aspartyl-glutamate sodium salt (NAAGA) on ocular active anaphylaxis. Allerg Immunol (Paris) 1996;28:124- 6.
25. Abelson MB, Schwartz E, Chapin MJ. Leukotrienes. In: Abelson MB, eds. Allergic diseases of the eye. Philadelphia: Saunders, 2000:93-8.
26. Elena PP, Goldschmidt P. Comparative evaluation of preserved and non preserved NAAGA eye-drops and nedocromil eye-drops on ocular active anaphylaxis. Jermov 97. Montpellier, France, October 15-19, 1997. Ophthalmic Res 2006;29:20.
27. Feuillard J, Maillet F, Goldschmidt P, et al. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA). Agents Actions 1991;32:343-6.
28. Goldschmidt P, Couturier C, Herman D, et al. Effects of three antiallergic drugs on the complement-induced degranulation C5a of human basophils obtained from patients suffering from allergy to pollen or acarians. ARVO. Fort Lauderdale, USA, May 14-19, 1995. Invest Ophthalmol Vis Sci 1995;36:658-B566.
29. Blondin C, Cholley B, Haeffner-Cavaillon N, et al. Effets modulateurs de collyres anti-allergiques sur l'activation du complément induite in vitro par des polluants particulaires. J Fr Ophtalmol 2003;26:328-36.
30. Bouhlal H, Blondin C, Haeffner-Cavaillon N, et al. Effets inhibiteurs du dipeptide N-acetyl-aspartyl-glutamate (NAAGA) sur l'adhérence des leucocytes humains aux cellules endothéliales activées et l'expression des molécules d'adhésion CD11b, CD49d, ICAM-1, ICAM-2, VCAM-1 et ELAM-1. J Fr Ophtalmol 2002;25:993-1000.
31. Yanez B, Martin R, Merayo-Lloves J, et al. Antiallergic efficacy of the antiallergic eye drop Lodoxamide 0.1% and Naaga 4.9% on ragweed-induced allergic conjunctivitis in mice. ARVO. Fort Lauderdale, USA, May 9-14, 1999. Invest Ophthalmol Vis Sci 1999;40:S686.
32. Osumi M, Yamada N, Toya M. Bacterial retention mechanisms of membrane filters. PDA J Pharm Sci Technol 1996;50:30-4.
33. Rigal D. Epithélium et thérapeutique. Epithélium et médicaments. In: Rigal D, Assouline M, Colin J, et al, eds. L'épithélium cornéen. Paris: Masson, 1993;XXVIII:391-419.